Working… Menu
Trial record 1 of 13 for:    CBD | Neuropathy
Previous Study | Return to List | Next Study

The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04088929
Recruitment Status : Recruiting
First Posted : September 13, 2019
Last Update Posted : September 19, 2019
Information provided by (Responsible Party):
Pure Green

Brief Summary:
Use of Cannabidiol for the treatment of Diabetic Neuropathic Pain.

Condition or disease Intervention/treatment Phase
Diabetic Neuropathies Drug: CBD Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Dose Controlled Diabetic Neuropathic Pain Study Using Non-Intoxicating Cannabidiol in a Rapidly Dissolvable Sublingual Tablet
Estimated Study Start Date : September 2019
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: CBD for Treatment of Diabetic Neuropathic Pain
Patients are instructed to take 3 total tablets a day, under the tongue, six hours apart for three weeks. Patients are to enter their pain scale score into the smartphone app as instructed during the initial site visit. Patients are to enter into the notes section of the app any additional information such as side effects (positive or negative), medication changes.
Drug: CBD
A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.

Primary Outcome Measures :
  1. Impact of Pure Green CBD tablets on diabetic neuropathy pain using a daily self-reported pain scale score. [ Time Frame: Three Weeks ]
    To evaluate the safety and efficacy of Pure Green CBD sublingual tablets for the treatment of chronic diabetic neuropathic pain patients by evaluating their daily pain scale score reported as 0-10 where 0 is no pain and 10 is the worst pain possible as self-reported with every dose taken by the patient in the smart phone app. The objective is to reduce the patients average daily pain scale score to less than 5.

Secondary Outcome Measures :
  1. Impact of Pure Green CBD tablets on the quality of life of Diabetic Neuropathy Patients [ Time Frame: Three Weeks ]
    To evaluate the impact of Pure Green CBD sublingual tablets on the quality of life of diabetic neuropathy patients measured by World Health Organization's quality of life questionnaire, . The objective is to examine quality of life metrics: overall quality of life and general health, physical health, psychological, social, and environment as measured on a 1-5 scale before and after the study.

  2. Impact of Pure Green CBD tablets on sleep improvement of Diabetic Neuropathy Patients [ Time Frame: Three weeks ]
    The Pittsburgh Sleep Quality Index will be used to compare pre and post Pure Green CBD tablet study on sleep changes. Patients will be asked questions before beginning the study and after completion.

  3. Impact of Pure Green CBD tablets on anxiety of Diabetic Neuropathy Patients [ Time Frame: Three Weeks ]
    The Hamilton Anxiety rating scale questionnaire will be administered before the study begins and after completion to examine the impact of Pure Green CBD tablets on anxiety in diabetic neuropathy pain patients. The scale of 0-4 will be used where 0 is no anxiety present and 4 is very severe anxiety.

  4. Impact on the use of sublingual tablets as the route of administration [ Time Frame: Three Weeks ]
    To explore the impact of sublingual administration on patient compliance by evaluating the number of tablets taken per day as entered by the patients into the smart phone app.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject is at least 21 years of age;
  2. Subject has a diagnosis of chronic diabetic neuropathic pain condition as determined by the subject's health care or allied health provider for which medications other than cannabis, cannabinoids, or cannabis-based medicines are currently utilized;
  3. Subject has a 7-day average pain scale score (recorded during the screening period) of ≥ 5;
  4. If female, subject is postmenopausal (> 1 year), surgically sterile, or practicing an approved method of birth control throughout the study and for 5 months (150 days) after the last dose of study drug;
  5. If female and of childbearing potential, subject has a denied pregnancy and has no desire to become pregnant throughout the duration of the study;
  6. Subject is willing and able to provide his/her written informed consent to participate in the study as stated in the informed consent document;
  7. Subject has access to a smart phone and knows how to use smart phone applications.

Exclusion Criteria:

  1. Subject is pregnant or lactating;
  2. Subject has an allergy to cannabis, the Cannabaceae plant family (e.g., hemp, hops, hackberry), PEA, terpenes, peppermint;
  3. Subject has a known allergy to active or inert ingredients of Pure Green tablets;
  4. Subject is currently treating their pain with cannabis, cannabinoids, cannabis-base medicine;
  5. Subject is taking a concomitant medication or treatment that would complicate use or interpretation of the study drug's effects (examples include: Cannabis or any cannabinoid products; Any drug or herbal product that influences the endocannabinoid system (ECS));
  6. Subject is taking marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD for at least 30 days prior to this study., and does not promise to not take marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD while participating in this study;
  7. Subject is currently being treated with antibiotics for sinus, throat, or lung infections;
  8. Subject has shortness of breath associated with allergies;
  9. Subject has uncontrolled asthma;
  10. Subject has a fever and/or productive cough;
  11. Subject does not have access to a smart phone or does not know how to use a smart phone application.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04088929

Layout table for location contacts
Contact: Heather Denham (228) 327-6339
Contact: Debra Kimless, M.D. (248) 920-8761

Layout table for location information
United States, Michigan
Dr. Nakadar's Office Recruiting
Sterling Heights, Michigan, United States, 48310
Contact: Heather Denham    228-327-6339   
Contact: Matthew Caloura    (248) 802-4380   
Sub-Investigator: Saqib Nakadar, D.O.         
Sponsors and Collaborators
Pure Green
Layout table for investigator information
Principal Investigator: Debra Kimless, M.D. Pure Green, LLC

Boulton AJ: Management of Diabetic Peripheral Neuropathy. Clinical Diabetes. 2005;23(1):9-15.

Layout table for additonal information
Responsible Party: Pure Green Identifier: NCT04088929     History of Changes
Other Study ID Numbers: PG-19-002
First Posted: September 13, 2019    Key Record Dates
Last Update Posted: September 19, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pure Green:
Neuropathic Pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Neuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases